BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Carando R, Pradere B, Afferi L, Marra G, Aziz A, Roghmann F, Krajewski W, Di Bona C, Alvarez-Maestro M, Pagliarulo V, Xylinas E, Moschini M. The role of device-assisted therapies in the management of non-muscle invasive bladder cancer: A systematic review. Prog Urol 2020;30:322-31. [PMID: 32279953 DOI: 10.1016/j.purol.2020.03.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
Number Citing Articles
1 Melgarejo Segura MT, Morales Martínez A, Yáñez Castillo Y, Arrabal Polo MÁ, Gómez Lechuga P, Pareja Vílchez M, Arrabal Martín M. Conductive hyperthermic chemotherapy versus electromotive drug administration of mitomycin C as intravesical adjuvant treatment of patients with intermediate or high-risk non-muscle invasive bladder cancer. Urol Oncol 2023;41:109.e1-8. [PMID: 36379812 DOI: 10.1016/j.urolonc.2022.10.019] [Reference Citation Analysis]
2 Du Z, Yin H, Zhao S, Ma Y, Sun Z, Dong B, Zhu M, Zhu C, Peng J, Yang T. Case report: Gemcitabine intravesical hyperthermic infusion combined with tislelizumab in muscle invasive bladder urothelium carcinoma. Front Oncol 2022;12:1062655. [PMID: 36620538 DOI: 10.3389/fonc.2022.1062655] [Reference Citation Analysis]
3 Yanagisawa T, Quhal F, Kawada T, Mostafaei H, Motlagh RS, Laukhtina E, Rajwa P, Deimling MV, Bianchi A, Pallauf M, Majdoub M, Pradere B, Moschini M, Karakiewicz PI, Teoh JY, Miki J, Kimura T, Shariat SF. A Systematic Review and Meta-analysis of Chemoablation for Non–muscle-invasive Bladder Cancer. European Urology Focus 2022. [DOI: 10.1016/j.euf.2022.12.003] [Reference Citation Analysis]
4 Melgarejo-segura MT, Morales-martínez A, Yáñez-castillo Y, Arrabal-polo MÁ, Gómez-lechuga P, Pareja-vílchez M, Jiménez-moleón JJ, Martín MA. A systematic review of the efficacy of intravesical electromotive drug administration therapy for non-muscle invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations 2022. [DOI: 10.1016/j.urolonc.2022.09.016] [Reference Citation Analysis]
5 Peyronnet B. Éditorial. Progrès en Urologie 2020;30:299-300. [DOI: 10.1016/j.purol.2020.05.003] [Reference Citation Analysis]
6 Rahimi-Gorji M, Van de Sande L, Debbaut C, Ghorbaniasl G, Braet H, Cosyns S, Remaut K, Willaert W, Ceelen W. Intraperitoneal aerosolized drug delivery: Technology, recent developments, and future outlook. Adv Drug Deliv Rev 2020;160:105-14. [PMID: 33132169 DOI: 10.1016/j.addr.2020.10.015] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 10.7] [Reference Citation Analysis]